The story of Viagra presents a nuanced case for observers in the medicinal sector. While initially a blockbuster success, generating vast sums, the patent expiration and the subsequent flood of generic alternatives have significantly changed revenue. This poses questions about the future sustainability of related drug innovations and suggests that